We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals
MIRM

112 hedge funds and large institutions have $673M invested in Mirum Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,640% more call options, than puts

Call options by funds: $374K | Put options by funds: $10K

71% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 28

25% more capital invested

Capital invested by funds: $540M → $673M (+$133M)

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

3% more funds holding

Funds holding: 109 → 112 (+3)

1.07% more ownership

Funds ownership: 92.11% → 93.18% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
112
Holders Change
+3
Holders Change %
+2.75%
% of All Funds
1.93%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
48
Reduced
28
Closed
14
Calls
$374K
Puts
$10K
Net Calls
+$364K
Net Calls Change
+$964K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$30.7M
2
State Street
State Street
Massachusetts
+$17.2M
3
Victory Capital Management
Victory Capital Management
Texas
+$15.5M
4
Citadel Advisors
Citadel Advisors
Florida
+$11.9M
5
WP
Woodline Partners
California
+$8.59M

Top Sellers

1
DM
Deerfield Management
New York
-$29.2M
2
NHAS
Novo Holdings A/S
Denmark
-$8.26M
3
MB
MPM BioImpact
Massachusetts
-$4.6M
4
IHAM
Integral Health Asset Management
New York
-$3.07M
5
EI
EAM Investors
California
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$3.48M -$291K -12,098 -7%
SAM
27
Silvercrest Asset Management
New York
$3.36M -$105K -4,350 -3%
Citigroup
28
Citigroup
New York
$2.9M +$3.28M +136,395 +7,702%
SCM
29
Soleus Capital Management
Connecticut
$2.85M -$1.45M -60,400 -31%
HP
30
Highlander Partners
Texas
$2.58M – – –
Two Sigma Advisers
31
Two Sigma Advisers
New York
$2.35M -$1.11M -46,100 -29%
Calamos Advisors
32
Calamos Advisors
Illinois
$2.28M +$1.59M +66,132 +156%
Prudential Financial
33
Prudential Financial
New Jersey
$2.21M -$1.36M -56,585 -35%
OCA
34
Octagon Capital Advisors
New York
$2.1M +$2.41M +100,000 New
MB
35
MPM BioImpact
Massachusetts
$2.04M -$4.6M -191,209 -66%
Morgan Stanley
36
Morgan Stanley
New York
$1.99M -$987K -40,992 -30%
Barclays
37
Barclays
United Kingdom
$1.87M +$1.58M +65,621 +282%
N
38
Nuveen
North Carolina
$1.76M +$1.08M +44,942 +116%
LPC
39
Lion Point Capital
New York
$1.72M +$1.93M +80,000 New
PAM
40
Panagora Asset Management
Massachusetts
$1.58M +$13.3K +551 +0.7%
RJA
41
Raymond James & Associates
Florida
$1.49M +$612K +25,439 +56%
PAI
42
Palo Alto Investors
California
$1.36M – – –
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.28M -$310K -12,872 -17%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$1.23M +$1.41M +58,547 New
Bank of America
45
Bank of America
North Carolina
$1.14M +$1.07M +44,626 +464%
Charles Schwab
46
Charles Schwab
California
$1.06M +$189K +7,842 +18%
RJFSA
47
Raymond James Financial Services Advisors
Florida
$1.06M -$374K -15,542 -24%
IHAM
48
Integral Health Asset Management
New York
$1.05M -$3.07M -127,427 -72%
Two Sigma Investments
49
Two Sigma Investments
New York
$1M -$1.77M -73,544 -61%
Swiss National Bank
50
Swiss National Bank
Switzerland
$987K +$231K +9,600 +26%
1
2
3 4 5

MIRM Hedge Fund Activity: Q3 2022 in Review

112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2022, worth a combined $673M — up 25% from $540M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MIRM positions and 14 closed out — a net gain of 3 holders — while 48 added to existing stakes and 28 trimmed.

The largest buyer was Eventide Asset Management, opening a new position worth an estimated $30.7M. The largest seller was Deerfield Management, cutting an estimated $29.2M.

  • 112 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2022, up from 109 in Q2 2022.
  • Funds reported $673M of Mirum Pharmaceuticals stock for Q3 2022, up 25% quarter-over-quarter.
  • 17 funds opened new Mirum Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of +3 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2022 was Eventide Asset Management, an estimated $30.7M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2022 was Deerfield Management, an estimated $29.2M sold.

Based on aggregated 13F filings for Q3 2022.